CASI Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- CASI Pharmaceuticals's estimated annual revenue is currently $8.8M per year.
- CASI Pharmaceuticals's estimated revenue per employee is $188,170
- CASI Pharmaceuticals's total funding is $147.4M.
Employee Data
- CASI Pharmaceuticals has 47 Employees.
- CASI Pharmaceuticals grew their employee count by 0% last year.
CASI Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | SVP | Reveal Email/Phone |
2 | VP, Global Financial Controller | Reveal Email/Phone |
3 | VP, Finance | Reveal Email/Phone |
4 | Chief Medical Officer | Reveal Email/Phone |
5 | Director, Supply and Manufacturing | Reveal Email/Phone |
6 | Chief Operating Officer | Reveal Email/Phone |
7 | Medical Director | Reveal Email/Phone |
8 | Regulatory Director | Reveal Email/Phone |
9 | President | Reveal Email/Phone |
10 | Legal Consultant | Reveal Email/Phone |
CASI Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $7M | 35 | -3% | N/A | N/A |
#2 | $7.2M | 36 | -5% | N/A | N/A |
#3 | $10.5M | 52 | -9% | N/A | N/A |
#4 | $344.1M | 1712 | 9% | N/A | N/A |
#5 | $27.5M | 137 | 6% | N/A | N/A |
#6 | $107.3M | 534 | 9% | N/A | N/A |
#7 | $12.9M | 64 | 28% | N/A | N/A |
#8 | $31.6M | 157 | 1% | N/A | N/A |
#9 | $31.4M | 156 | 7% | N/A | N/A |
#10 | $11.5M | 57 | 30% | N/A | N/A |
What Is CASI Pharmaceuticals?
EntreMed, Inc. is a clinical-stage biopharmaceutical company that develops and tests product candidates that address the role of blood and blood vessels in health and disease. Angiogenesis is the biological process by which new blood vessels are formed. As "The Angiogenesis Company," EntreMed is primarily focused on developing antiangiogenic drugs designed to inhibit the abnormal new blood vessel growth associated with cancer, as well as a broad range of diseases including certain types of blindness and atherosclerosis. EntreMed's current portfolio of antiangiogenic product candidates includes Endostatin, Panzem and Angiostatin, the patent rights for all of which are exclusively licensed to the Company by Children's Hospital, Boston.
keywords:N/A
$147.4M
Total Funding
47
Number of Employees
$8.8M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
CASI Pharmaceuticals News
CASI Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the...
CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and...
CASI PHARMACEUTICALS ANNOUNCES FULL-YEAR 2021 FINANCIAL RESULTS AND FOURTH QUARTER 2021 EVOMELA® REVENUE. CASI Pharmaceuticals logo (PRNewsFoto/...
ROCKVILLE, Md., and BEIJING, Nov. 15, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announces that Mr. Larry Zhang, President of CASI Pharmaceut ...
ROCKVILLE, Md. and BEIJING, Nov. 12, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the third quarter of 2021. ...
Other Companies in Rockville
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | N/A | 47 | 4% | N/A |
#2 | $9.4M | 47 | 0% | N/A |
#3 | N/A | 48 | 2% | N/A |
#4 | $8.1M | 48 | 9% | N/A |
#5 | $10.4M | 48 | 14% | N/A |